Eli Lilly hikes weight-loss drug prices in Canada after pressure from Trump

U.S. drugmaker Eli Lilly & Co. LLY-N has increased prices of its popular diabetes and anti-obesity drugs in Canada as it responds to pressure from the Trump administration to lower prices in the U.S. and raise them elsewhere.

The company also announced it is sharply raising prices in the U.K. to match those of other European markets.

The moves make the company one of the most high-profile so far to respond U.S. President Donald Trump’s direction to rebalance global prices.

“Lilly supports the administration’s goal of keeping the United States the world’s leading destination for biopharmaceutical research and manufacturing, and the objective of more fairly sharing the costs of breakthrough medical research across developed countries,” the company said Thursday in an unsigned statement.